Last updated: October 22, 2021
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Overall Status: Active - Recruiting
Phase
N/A
Condition
Late Infantile Neuronal Ceroid Lipfuscinsosis
Infantile Neuronal Ceroid Lipofuscinosis
Neuronal Ceroid Lipofuscinoses (Ncl)
Treatment
N/AClinical Study ID
NCT04613089
DEM-CHILD2020
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with a confirmed molecular diagnosis of a form of NCL Disease Additional inclusion criteria for Group/Cohort: "CLN2 Disease - ERT (Brineura) Treated":
- Documented diagnosis of TPP1 deficiency
- Previous or current treatment with intracerebroventricular ERT with cerliponase alpha
- Patients that are currently participating in post-marketing studies will be allowed toparticipate.
Exclusion
Exclusion Criteria:
- Patients with no confirmed molecular diagnosis of a form of NCL Disease
Study Design
Total Participants: 500
Study Start date:
April 08, 2020
Estimated Completion Date:
April 08, 2050
Study Description
Connect with a study center
University Medical Center Hamburg-Eppendorf
Hamburg, 20246
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.